Hologic (NASDAQ:HOLX) Upgraded by Wall Street Zen to “Buy” Rating

Hologic (NASDAQ:HOLX) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

A number of other research analysts also recently weighed in on HOLX. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. UBS Group increased their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. Finally, Evercore ISI upped their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $78.00.

Hologic Stock Performance

HOLX stock opened at $66.54 on Friday. The business’s fifty day moving average is $66.37 and its 200-day moving average is $62.60. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.80 billion, a P/E ratio of 27.61, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic will post 4.28 EPS for the current year.

Hedge Funds Weigh In On Hologic

A number of large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares in the last quarter. Invesco Ltd. increased its holdings in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Geode Capital Management LLC increased its holdings in Hologic by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after purchasing an additional 97,142 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after purchasing an additional 69,878 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.